365 Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC)

Abstract

BackgroundThe pathologist’s visual assessment of tumor proportion score (TPS) with 25% cutoff on PD-L1 stained tissue samples is an established method to select metastatic NSCLC patients that are likely to respond to an anti-PD-L1 monotherapy.1 However, manual scoring is often subject to subjectivity in human perception2 and there remains a critical need for more objective and quantitative methods to assess PD-L1 expression in immuno-oncology.MethodsWe used deep learning (DL) based image analysis (IA) to generate a novel PD-L1 Quantitative Continuous Score (QCS)3 in tumor cells. PD-L1 QCS consists of two DL models to first segment epithelial regions and second detect membranes, cytoplasm and nuclei of each tumor cell in PD-L1 immunohistochemically (IHC) stained tissue slides. The PD-L1 expression of each tumor cell compartment was estimated by the respective optical density (OD) of DAB, and tumor cells with a membrane OD greater than ODmin are considered as PD-L1-positive. A slide comprising at greater percentage of PD-L1-positive tumor cells than a cutoff value (CoV) is considered QCS-positive. The ODmin and CoV parameters were linked to patient overall survival (OS), by minimizing the Kaplan Meier log-rank p-values and keeping at least 50% prevalence in the QCS-positive subgroup.Fully supervised QCS-IA models were extensively trained using pathologists’ annotations and the performance was validated on unseen data to ensure its generalization and robustness.3 4 The QCS IA was locked and blindly applied on clinical trial data (NCT01693562, durvalumab-treated late-stage NSCLC cohort) without further refinement.ResultsData analytics techniques were used to determine optimal PD-L1 QCS parameters for the clinical trial cohort of N=162 late-stage NSCLC patients. A PD-L1 QCS algorithm (ODmin=8, CoV=57%) is able to stratify durvalumab-treated NSCLC patients at a higher prevalence and more significant log rank p-value (64%, p=0.0001) for OS (figure 1) compared to pathologist TPS (59%, p=0.01). Median OS times of (19.2 months vs 7.9 months) was observed in the QCS-positive vs negative subgroups, respectively. The box plots (figure 2) indicate an overall good agreement (72% concordance) of the fully automated QCS with the pathologists TPS, which quantitatively supports the positive visual assessment of the cell segmentation accuracy.Abstract 365 Figure 1Kaplan Meier (KM) curves for OS stratification. KM curves for Overall Survival (OS) stratification with (left) manual PD-L1 TPS score (25% cutoff), and (right) automated QCS (57% cutoff).Abstract 365 Figure 2QCS scores within TPS positive and negative groups. Box plot indicating percent positive cells (OD≥8) as measured by PD-L1 QCS within the PD-L1 high (red) and low (blue) groups as per pathologist assessment by TPS.ConclusionsThe novel Quantitative Continuous Scoring (QCS) provides an objective way of correlating a quantitative estimate of PD-L1 IHC expression on tumor cells with survival of durvalumab-treated NSCLC patients. This data establishes a first proof-of-concept demonstrating the potential utility of PD-L1 QCS towards precision medicine in immuno-oncology.ReferencesRebelatto M, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathology 2016.Tsao M S, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. Journal of Thoracic Oncology 2018.Gustavson M, et al. Novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients. (2021) DOI: 10.1158/1538-7445.SABCS20-PD6-01Kapil A, et al. Domain adaptation-based deep learning for automated tumor cell (TC) scoring and survival analysis on PD-L1 stained tissue images. IEEE Transactions on Medical Imaging DOI: 10.1109/TMI.2021.3081396Ethics ApprovalClinical study NCT01693562, from which data in this report were obtained, was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol, amendments, and participant informed consent document were approved by the appropriate institutional review boards.

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

“…QCS-based analysis provides flexibility to tailor scoring schemes to different MOAs of the investigated drugs, which provides a potential opportunity for wide applications of QCS-based biomarker analysis. To support this, we performed a successful QCS-based analysis on a data set of durvalumab-treated (anti–programmed death-ligand 1 [PD-L1]) patients with late-stage non–small cell lung cancer 11 (see Supplementary Figs. S3 , S4 , S5 ).…”

HER2 quantitative continuous scoring for accurate patient selection in HER2-negative trastuzumab deruxtecan–treated breast cancer

“…QCS-based analysis provides exibility to tailor scoring schemes to different MOAs of the investigated drugs, which provides a potential opportunity for wide applications of QCS-based biomarker analysis. To support this, we performed a successful QCS-based analysis on a data set of durvalumab-treated (antiprogrammed death-ligand 1 [PD-L1]) patients with late-stage non-small cell lung cancer 11 (see Supplementary Fig. S3, Fig.…”

579 Novel digital image approach of multiplex immunofluorescence based PD-L1 expression enables the stratification of advanced NSCLC patients treated with durvalumab

“…[2][3] Quantitative Continuous Scoring (QCS) 4 enables the continuous measurement of the PD-L1 expression on single cells and the selection of the PD-L1 expression cutoff that best stratifies anti-PD-L1-treated patients with respect to prevalence and log-rank test p-value. 5 We present here the extension of QCS to PD-L1 measured by multiplex immunofluorescence (mIF) 6 to evaluate its ability to optimize patient stratification. Methods Pre-treatment tumor samples from advanced NSCLC patients enrolled in durvalumab nonrandomized phase 1/2 trial (CP1108/NCT01693562) 2 , were stained by mIF panel containing PD-L1.…”